Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 8/20 | 0.55 |
| ▸ | METAP2 | P50579 | 5/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cambendazole SCHEMBL29409263 | 0.92 | METAP1 (0.48) | METAP1METAP2CA12CA1CA2 | |
| Cambendazole SCHEMBL44000 | 0.92 | METAP1 (0.48) | METAP1METAP2CA12CA1CA2 | |
| Cambendazole SCHEMBL8734398 | 0.89 | METAP1 (0.57) | METAP1METAP2KDM4ETP53SMN1; SMN2 | |
| SCHEMBL3500750 | 0.89 | METAP1 (0.59) | METAP1METAP2CA12CA1CA2 | |
| Diethenofencarb SCHEMBL9055860 | 0.84 | HPSE (0.51) | METAP1METAP2KDM4ETP53SMN1; SMN2 | |
| SCHEMBL11208586 | 0.83 | METAP1 (0.63) | METAP1METAP2CA12CA1CA2 | |
| SCHEMBL4368578 | 0.81 | METAP1 (0.58) | METAP1METAP2CA12CA1CA2 | |
| SCHEMBL3500748 | 0.81 | METAP1 (0.52) | METAP1METAP2CA12CA1CA2 | |
| SCHEMBL13624132 | 0.80 | METAP1 (0.64) | METAP1METAP2CA12CA1CA2 | |
| SCHEMBL4369556 | 0.79 | METAP1 (0.56) | METAP1METAP2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117193223-B | Plastic product production control system | 南通瑞童塑业科技有限公司 | 2024-04-05 | — | — | CN | claimed |
| US-20240066035-A1 | Methods for Enhancing Cytotoxic Cancer Therapy Through Inhibition of ATG4B | NORTHWESTERN UNIVERSITY | 2024-02-29 | — | — | US | claimed |
| CN-117193223-A | Plastic product production control system | 南通瑞童塑业科技有限公司 | 2023-12-08 | — | — | CN | claimed |
| US-11793816-B2 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | NORTHWESTERN UNIVERSITY (US) | 2023-10-24 | — | — | US | claimed |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | SANTOLECAN PHARMACEUTICALS LLC | 2021-07-29 | — | — | US | claimed |
| EP-3812376-A1 | PACLITAXEL-LIPID-POLYSACCHARIDE DUAL-TYPE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Santolecan Pharmaceuticals LLC (US) | 2021-04-28 | — | — | EP | claimed |
| US-20210069202-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH INHIBITION OF ATG4B | NORTHWESTERN UNIVERSITY | 2021-03-11 | — | — | US | claimed |
| CN-111886499-A | Methods based on detection of RAD51 focus in tumor cells | 瓦尔希伯伦私人肿瘤研究基金会 | 2020-11-03 | — | — | CN | claimed |
| CN-110678543-A | In vitro culture system and method of use | 耶达研究及发展有限公司 | 2020-01-10 | — | — | CN | claimed |
| CN-108519453-A | A kind of assay method of 19 kinds of benzimidazoles residues residual quantities based on isotopic dilution-editable multiple-reaction monitoring pattern | 广东出入境检验检疫局检验检疫技术中心 | 2018-09-11 | — | — | CN | claimed |
| CN-104341409-B | A kind of thiabendazole haptens preparation method and applications | 北京勤邦生物技术有限公司 | 2017-11-28 | — | — | CN | claimed |
| CN-104341409-A | Thiabendazole hapten preparation method and application | BEIJING KWINBON BIOTECH CO LTD | 2015-02-11 | — | — | CN | claimed |
| CN-101035530-A | VEGF inhibition | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2007-09-12 | — | — | CN | claimed |
| CN-1173331-A | Process for production of anthelmintic composition for animal use | PFIZER (US) | 1998-02-18 | — | — | CN | claimed |
| CN-1053549-A | Antiparasitic composition for animals | SMITHKLINE BEECHAM CORP (US) | 1991-08-07 | — | — | CN | claimed |
| EP-0059074-B1 | ANTHELMINTIC COMPOSITION AND THE USE THEREOF | SANKYO COMPANY LIMITED (JP) | 1984-10-10 | — | — | EP | claimed |
| US-4468390-A | Anthelmintic composition and the use thereof | SANKYO COMPANY, LIMITED (JP) | 1984-08-28 | — | — | US | claimed |
| EP-0059074-A1 | Anthelmintic composition and the use thereof | SANKYO COMPANY LIMITED (JP) | 1982-09-01 | — | — | EP | claimed |
| US-12576088-B2 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | NORTHWESTERN UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-4021438-A | Novel process for the preparation of thiazoles | MERCK & CO., INC. (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066035-A1 | Methods for Enhancing Cytotoxic Cancer Therapy Through Inhibition of ATG4B | ATG4B, ATG4A, ATG7 | METAP1 1337/4885METAP2 1180/4885CA12 3851/4885 |
| US-20210069202-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH INHIBITION OF ATG4B | ATG4B, ATG4A, ATG7 | METAP1 1337/4885METAP2 1180/4885CA12 3851/4885 |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | DDOST, UGT2B17, UGT1A7 | METAP1 4638/4885METAP2 4482/4885CA12 668/4885 |
| US-11793816-B2 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | ATG4B, ATG4A, ATG7 | METAP1 1337/4885METAP2 1180/4885CA12 3851/4885 |
| US-12576088-B2 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | ATG4B, ATG4A, ATG7 | METAP1 1551/4885METAP2 954/4885CA12 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.